CY1120474T1 - Χημικες ενωσεις - Google Patents
Χημικες ενωσειςInfo
- Publication number
- CY1120474T1 CY1120474T1 CY20181100009T CY181100009T CY1120474T1 CY 1120474 T1 CY1120474 T1 CY 1120474T1 CY 20181100009 T CY20181100009 T CY 20181100009T CY 181100009 T CY181100009 T CY 181100009T CY 1120474 T1 CY1120474 T1 CY 1120474T1
- Authority
- CY
- Cyprus
- Prior art keywords
- chemical compounds
- compounds
- pharmaceutically
- processes
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361827951P | 2013-05-28 | 2013-05-28 | |
| US201361915685P | 2013-12-13 | 2013-12-13 | |
| PCT/GB2014/051607 WO2014191726A1 (en) | 2013-05-28 | 2014-05-27 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120474T1 true CY1120474T1 (el) | 2019-07-10 |
Family
ID=50841880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181100009T CY1120474T1 (el) | 2013-05-28 | 2018-01-03 | Χημικες ενωσεις |
Country Status (35)
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013096744A1 (en) | 2011-12-21 | 2013-06-27 | Novira Therapeutics, Inc. | Hepatitis b antiviral agents |
| AU2013307331A1 (en) | 2012-08-28 | 2015-02-19 | Janssen Sciences Ireland Uc | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of Hepatitis B |
| PT2961732T (pt) | 2013-02-28 | 2017-06-26 | Janssen Sciences Ireland Uc | Sulfamoil-arilamidas e utilização das mesmas como medicamentos para o tratamento de hepatite b |
| EA027068B1 (ru) | 2013-04-03 | 2017-06-30 | Янссен Сайенсиз Айрлэнд Юси | Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| CN105960400B (zh) | 2013-05-17 | 2019-05-31 | 爱尔兰詹森科学公司 | 氨磺酰基噻吩酰胺衍生物及其作为药物用于治疗乙型肝炎的用途 |
| AU2014294997B2 (en) | 2013-07-25 | 2018-03-22 | Janssen Sciences Ireland Uc | Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| JP6452119B2 (ja) | 2013-10-23 | 2019-01-16 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | カルボキサミド誘導体およびｂ型肝炎の処置のための医薬品としてのその使用 |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US9169212B2 (en) | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US20150216938A1 (en) | 2014-02-05 | 2015-08-06 | Novira Therapeutics Inc. | Combination therapy for treatment of hbv infections |
| UY35980A (es) | 2014-02-06 | 2015-08-31 | Janssen Sciences Ireland Uc | Derivados de sulfamoilpirrolamida como inhibidores del hbv y composiciones farmacéuticas que los contienen |
| RS60824B1 (sr) | 2014-12-18 | 2020-10-30 | Hoffmann La Roche | Tetrahidro-pirido[3,4-b]indoli kao modulatori estrogenih receptora i njihova upotreba |
| WO2016146591A1 (en) * | 2015-03-16 | 2016-09-22 | Astrazeneca Ab | Combination treatment |
| CA2980298A1 (en) | 2015-03-19 | 2016-09-22 | Novira Therapeutics, Inc. | Azocane and azonane derivatives and methods of treating hepatitis b infections |
| WO2016202161A1 (zh) * | 2015-06-16 | 2016-12-22 | 江苏恒瑞医药股份有限公司 | 哌啶类衍生物、其制备方法及其在医药上的应用 |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| CN108350062B (zh) | 2015-08-06 | 2022-10-14 | 达纳-法伯癌症研究所股份有限公司 | 靶向蛋白降解以减弱过继性t细胞疗法相关的不良炎症反应 |
| US10077239B2 (en) | 2015-09-29 | 2018-09-18 | Novira Therapeutics, Inc. | Crystalline forms of a hepatitis B antiviral agent |
| NZ779654A (en) * | 2015-10-01 | 2024-12-20 | Olema Pharmaceuticals Inc | Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs |
| CA3011391C (en) * | 2015-11-12 | 2021-02-09 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Acrylic acid derivative, preparation method and use in medicine thereof |
| EP3386968B1 (en) | 2015-12-09 | 2025-04-02 | The Board of Trustees of the University of Illinois | Benzothiophene-based selective estrogen receptor downregulator compounds |
| BR112018011817A2 (pt) | 2015-12-22 | 2018-12-04 | Jiangsu Hengrui Medicine Co | derivado de benzopiperidina, método de preparação do mesmo, e uso médico do mesmo |
| DK3411034T3 (da) * | 2016-02-05 | 2021-01-11 | Inventisbio Inc | Selektiv østrogenreceptornedbrydere og anvendelser deraf |
| KR20220071293A (ko) * | 2016-04-01 | 2022-05-31 | 리커리엄 아이피 홀딩스, 엘엘씨 | 에스트로겐 수용체 조절제 |
| MA44671A (fr) | 2016-04-15 | 2019-02-20 | Janssen Sciences Ireland Uc | Associations et méthodes comprenant un inhibiteur d'ensemble capside |
| WO2017182493A1 (en) | 2016-04-20 | 2017-10-26 | Astrazeneca Ab | Indazole derivatives for use in down-regulation of the estrogen receptor for the treatment of cancer |
| WO2017189976A1 (en) | 2016-04-29 | 2017-11-02 | Board Of Regents, The University Of Texas System | Targeted measure of transcriptional activity related to hormone receptors |
| CN109661393A (zh) * | 2016-05-08 | 2019-04-19 | 上海诚妙医药科技有限公司 | 帕布昔利布的新晶型及其制备方法及其用途 |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| EP3472162B1 (en) * | 2016-06-16 | 2021-11-17 | F. Hoffmann-La Roche AG | Heteroaryl estrogen receptor modulators and uses thereof |
| JP2019521983A (ja) | 2016-06-16 | 2019-08-08 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | テトラヒドロ−ピリド［３，４−ｂ］インドールエストロゲン受容体モジュレーター及びその使用 |
| WO2018001232A1 (zh) * | 2016-06-29 | 2018-01-04 | 浙江海正药业股份有限公司 | 丙烯酸类衍生物及其制备方法和其在医药上的用途 |
| RU2019102647A (ru) | 2016-07-01 | 2020-08-03 | Г1 Терапьютикс, Инк. | Антипролиферационные средства на основе пиримидина |
| TW201815789A (zh) | 2016-07-25 | 2018-05-01 | 瑞典商阿斯特捷利康公司 | 化合物 |
| CN107814798B (zh) * | 2016-09-14 | 2020-11-03 | 四川科伦博泰生物医药股份有限公司 | 3-取代丙烯酸类化合物及其制备方法和用途 |
| CN110139674B (zh) | 2016-10-05 | 2023-05-16 | 豪夫迈·罗氏有限公司 | 制备抗体药物缀合物的方法 |
| LT3433256T (lt) | 2016-10-24 | 2019-11-11 | Astrazeneca Ab | 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izochinolino darinys, naudingas vėžio gydymui |
| WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
| AU2018205262A1 (en) | 2017-01-06 | 2019-07-11 | G1 Therapeutics, Inc. | Combination therapy for the treatment of cancer |
| WO2018130123A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的五环类化合物及其应用 |
| WO2018130124A1 (zh) * | 2017-01-11 | 2018-07-19 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的三环类化合物及其应用 |
| MA52555A (fr) * | 2017-01-30 | 2021-03-17 | Astrazeneca Ab | Modulateurs du récepteur des oestrogènes |
| AU2018219289A1 (en) | 2017-02-08 | 2019-09-05 | Dana-Farber Cancer Institute, Inc. | Regulating chimeric antigen receptors |
| WO2018148576A1 (en) | 2017-02-10 | 2018-08-16 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
| CN108864080B (zh) * | 2017-05-09 | 2021-10-15 | 南京圣和药业股份有限公司 | 作为选择性雌激素受体下调剂的四环类化合物及其应用 |
| CN110536888B (zh) * | 2017-06-20 | 2022-07-26 | 江苏恒瑞医药股份有限公司 | 一种苯并哌啶类衍生物的盐、其晶型及盐、其晶型的制备方法 |
| EP3641762A4 (en) | 2017-06-20 | 2021-03-10 | C4 Therapeutics, Inc. | N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION |
| FI3645001T3 (fi) | 2017-06-29 | 2024-09-25 | G1 Therapeutics Inc | Git38:n morfisia muotoja ja niiden valmistusmenetelmiä |
| TW202428622A (zh) | 2017-10-18 | 2024-07-16 | 瑞士商諾華公司 | 用於選擇性蛋白質降解的組合物及方法 |
| EA038160B1 (ru) * | 2017-11-30 | 2021-07-15 | Астразенека Аб | Модуляторы рецептора эстрогена |
| CN109867659A (zh) * | 2017-12-04 | 2019-06-11 | 江苏恒瑞医药股份有限公司 | 苯并哌啶类衍生物的制备方法 |
| US10519152B2 (en) | 2017-12-21 | 2019-12-31 | Astrazeneca Ab | Compounds and their use in treating cancer |
| CN112041294B (zh) * | 2018-02-23 | 2024-02-20 | 晶体工程智能研究中心 | 泛醇的共晶和包含所述共晶的组合物 |
| EA202092171A1 (ru) | 2018-03-14 | 2020-12-01 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Схема дозирования модулятора сборки капсида |
| WO2019222272A1 (en) | 2018-05-14 | 2019-11-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| WO2019228443A1 (en) * | 2018-05-30 | 2019-12-05 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Selective estrogen receptor downregulators and uses thereof |
| PL3810283T3 (pl) | 2018-06-21 | 2023-10-16 | F. Hoffmann-La Roche Ag | Postacie stałe soli winianowej 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropylo)azetydyn-3-ylo)amino)fenylo)-3-metylo-1,3,4,9-tetrahydro-2H-pirydo[3,4-b]indol-2-ilo)-2,2-difluoropropan-1-olu, sposób ich otrzymywania i sposoby ich zastosowania w leczeniu nowotworów |
| MA53105A (fr) | 2018-07-03 | 2021-05-12 | Univ Illinois | Activateurs de la réponse à une protéine non dépliée |
| WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
| KR102736733B1 (ko) * | 2018-12-24 | 2024-11-29 | 인벤티스바이오 컴퍼니 리미티드 | 선택적 에스트로겐 수용체 분해제의 신규 염 |
| KR20210130753A (ko) | 2019-02-22 | 2021-11-01 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | Hbv 감염 또는 hbv-유발성 질환의 치료에 유용한 아미드 유도체 |
| WO2020219742A1 (en) | 2019-04-24 | 2020-10-29 | Novartis Ag | Compositions and methods for selective protein degradation |
| MA55879A (fr) | 2019-05-06 | 2022-03-16 | Janssen Sciences Ireland Unlimited Co | Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b |
| BR112021022008A2 (pt) * | 2019-05-14 | 2022-05-17 | Nuvation Bio Inc | Compostos de direcionamento a receptor de hormônio nuclear anticâncer |
| JP7616794B2 (ja) | 2019-07-07 | 2025-01-17 | オレマ ファーマシューティカルズ インク． | エストロゲン受容体アンタゴニストのレジメン |
| KR20220044528A (ko) | 2019-08-06 | 2022-04-08 | 리커리엄 아이피 홀딩스, 엘엘씨 | 돌연변이체를 치료하기 위한 에스트로겐 수용체 조절제 |
| US20220389006A1 (en) * | 2019-11-04 | 2022-12-08 | Recurium Ip Holdings, Llc | Salts and forms of an estrogen receptor modulator |
| TW202131930A (zh) | 2019-11-13 | 2021-09-01 | 美商諾維雪碧歐公司 | 抗癌核荷爾蒙受體標靶化合物 |
| IL293999B1 (en) | 2019-12-20 | 2025-10-01 | C4 Therapeutics Inc | Isoindolinone compounds with a phenylaminoglutarimide residue for degradation of EGFR |
| CN116731064A (zh) | 2020-01-10 | 2023-09-12 | 江苏恒瑞医药股份有限公司 | 三环四氢异喹啉类衍生物、其制备方法及其在医药上的应用 |
| CA3165309A1 (en) | 2020-03-05 | 2021-09-10 | Christopher G. Nasveschuk | Compounds for targeted degradation of brd9 |
| AU2021230588A1 (en) | 2020-03-06 | 2022-08-25 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
| IL297218A (en) | 2020-04-24 | 2022-12-01 | Astrazeneca Ab | Pharmaceutical formulations |
| EP4138834A1 (en) | 2020-04-24 | 2023-03-01 | Astrazeneca AB | Dosage regimen for the treatment of cancer |
| WO2021253380A1 (en) * | 2020-06-19 | 2021-12-23 | InventisBio Co., Ltd. | Oral formulations and uses thereof |
| US20230263734A1 (en) * | 2020-08-05 | 2023-08-24 | Aizant Drug Research Solutions Private Limited | Solid dosage forms of palbociclib |
| CN116490186B (zh) | 2020-08-05 | 2025-10-31 | C4医药公司 | 用于ret的靶向降解的化合物 |
| EP4247977A2 (en) | 2020-11-23 | 2023-09-27 | Sanofi | Panel of er regulated genes for use in monitoring endocrine therapy in breast cancer |
| JP2024502270A (ja) | 2020-12-23 | 2024-01-18 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | エストロゲン受容体調節薬 |
| WO2022204184A1 (en) | 2021-03-23 | 2022-09-29 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| AU2022269568A1 (en) | 2021-05-03 | 2023-11-16 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| CN117940133A (zh) | 2021-06-08 | 2024-04-26 | C4医药公司 | 用于突变braf的降解的治疗剂 |
| AU2022305957A1 (en) * | 2021-07-08 | 2024-01-25 | Olema Pharmaceuticals, Inc. | Methods of treating estrogen receptor-associated diseases |
| TW202317582A (zh) | 2021-07-09 | 2023-05-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 三環四氫異喹啉類衍生物的鹽型 |
| WO2023221123A1 (en) * | 2022-05-20 | 2023-11-23 | Olema Pharmaceuticals, Inc. | Crystalline forms of an estrogen receptor antagonist |
| CN119998285A (zh) | 2022-08-03 | 2025-05-13 | 百时美施贵宝公司 | 用于调控ret蛋白的化合物 |
| WO2024097989A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein degraders |
| CN120530116A (zh) | 2022-11-04 | 2025-08-22 | 百时美施贵宝公司 | Ret-ldd蛋白抑制剂 |
| KR20240170460A (ko) * | 2023-05-25 | 2024-12-03 | 주식회사 삼양홀딩스 | 팔보시클립의 경구용 조성물 |
| WO2025006753A2 (en) | 2023-06-30 | 2025-01-02 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| AU2381497A (en) | 1996-04-19 | 1997-11-12 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
| FR2778404B1 (fr) * | 1998-05-06 | 2000-06-30 | Hoechst Marion Roussel Inc | Derives du dihydro ou tetrahydronaphtalene, et les compositions pharmaceutiques les renfermant |
| GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
| ATE368037T1 (de) | 1999-04-28 | 2007-08-15 | Sanofi Aventis Deutschland | Di-aryl-säurederivate als ppar rezeptor liganden |
| FR2796644B1 (fr) * | 1999-07-23 | 2001-09-07 | Adir | Nouveaux derives de beta-carboline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| YU65502A (sh) * | 2000-03-15 | 2005-11-28 | Aventis Pharma Deutschland Gmbh. | Supstituisani beta-karbolini sa ikb-kinaza inhibirajućim dejstvom |
| US6720331B2 (en) | 2001-04-03 | 2004-04-13 | National Sun Yat-Sen University | 1-substituted 1,2,3,4-tetrahydro-β-carboline and 3,4-dihydro-β-carboline and analogs as antitumor agents |
| JP2005516967A (ja) | 2002-01-18 | 2005-06-09 | ザ ジェネティクス カンパニー インコーポレーティッド | β−セクレターゼインヒビター |
| JP2005529876A (ja) | 2002-04-22 | 2005-10-06 | ジョンズ ホプキンス ユニバーシティー スクール オブ メディシン | Ｈｅｄｇｅｈｏｇシグナル伝達経路の調節因子、それに関連する組成物および使用 |
| TWI329111B (en) | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| US20050004164A1 (en) | 2003-04-30 | 2005-01-06 | Caggiano Thomas J. | 2-Cyanopropanoic acid amide and ester derivatives and methods of their use |
| JP4671123B2 (ja) | 2003-06-23 | 2011-04-13 | 小野薬品工業株式会社 | 新規三環性複素環化合物 |
| BRPI0413013A (pt) * | 2003-07-28 | 2006-10-03 | Smithkline Beecham Corp | composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças |
| DE10335725A1 (de) | 2003-08-05 | 2005-03-03 | Bayer Cropscience Gmbh | Safener auf Basis aromatisch-aliphatischer Carbonsäuredarivate |
| BRPI0506977A (pt) * | 2004-01-23 | 2007-07-03 | Chiron Corp | composto de tetrahidrocarbolina como agentes anticáncer |
| ATE394399T1 (de) * | 2004-03-11 | 2008-05-15 | Actelion Pharmaceuticals Ltd | Tetrahydropyridoindolderivate |
| US8076352B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| GB0422057D0 (en) | 2004-10-05 | 2004-11-03 | Astrazeneca Ab | Novel compounds |
| WO2006050212A1 (en) | 2004-10-28 | 2006-05-11 | The Institutes For Pharmaceutical Discovery Llc | Substituted carboxylic acids |
| WO2006055625A2 (en) | 2004-11-18 | 2006-05-26 | The Institutes For Pharmaceutical Discovery, Llc | Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors |
| JP2008530136A (ja) | 2005-02-14 | 2008-08-07 | ミイカナ セラピューティクス インコーポレイテッド | ヒストンデアセチラーゼの阻害剤として有用な縮合複素環化合物 |
| TW200716628A (en) * | 2005-03-22 | 2007-05-01 | Astrazeneca Ab | Novel compounds |
| US20070032385A1 (en) | 2005-06-20 | 2007-02-08 | Dunetz Joshua R | Sustainable chemical processes |
| US20080075692A1 (en) | 2006-05-09 | 2008-03-27 | Perrine Susan P | Methods for treating blood disorders |
| MX2009001946A (es) | 2006-08-23 | 2009-03-05 | Kudos Pharm Ltd | Derivados de 2-metilmorfolin-pirido-, pirazo- y pirimido- pirimidina como inhibidores de mtor. |
| JP2010503615A (ja) | 2006-08-29 | 2010-02-04 | レインナーベート リミテッド | レチノイド化合物およびそれらの使用 |
| WO2008124836A2 (en) | 2007-04-10 | 2008-10-16 | Uwm Research Foundation, Inc. | Methods of reducing virulence in bacteria |
| WO2008124838A1 (en) | 2007-04-10 | 2008-10-16 | University Of Maryland, Baltimore | Compounds that inhibit human dna ligases and methods of treating cancer |
| WO2008127714A1 (en) | 2007-04-13 | 2008-10-23 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
| WO2009011836A1 (en) | 2007-07-19 | 2009-01-22 | Merck & Co., Inc. | Beta carboline derivatives as antidiabetic compounds |
| US8198292B2 (en) * | 2008-07-03 | 2012-06-12 | Osteogenex, Inc. | Vinpocetine and eburnamonine derivatives for promoting bone growth, treating renal damage and cancer, and devices thereof |
| TW201028414A (en) | 2009-01-16 | 2010-08-01 | Merck Sharp & Dohme | Oxadiazole beta carboline derivatives as antidiabetic compounds |
| US20120135089A1 (en) | 2009-03-17 | 2012-05-31 | Stockwell Brent R | E3 ligase inhibitors |
| WO2010138706A1 (en) | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating breast cancer |
| WO2010138758A1 (en) * | 2009-05-27 | 2010-12-02 | Ptc Therapeutics, Inc. | Methods for treating cancer and non-neoplastic conditions |
| WO2012112965A1 (en) | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | Compounds and methods of treating diabetes |
| WO2013022740A2 (en) | 2011-08-05 | 2013-02-14 | Corning Incorporated | Gpr35 ligands and the uses thereof |
-
2014
- 2014-05-27 PT PT147270367T patent/PT3004090T/pt unknown
- 2014-05-27 SM SM20170589T patent/SMT201700589T1/it unknown
- 2014-05-27 RU RU2015151502A patent/RU2664109C2/ru active
- 2014-05-27 SI SI201430531T patent/SI3004090T1/en unknown
- 2014-05-27 AP AP2015008858A patent/AP2015008858A0/xx unknown
- 2014-05-27 RS RS20171304A patent/RS56678B1/sr unknown
- 2014-05-27 EP EP14727036.7A patent/EP3004090B1/en active Active
- 2014-05-27 EP EP17196495.0A patent/EP3360875A1/en not_active Withdrawn
- 2014-05-27 KR KR1020157036820A patent/KR20160013198A/ko not_active Ceased
- 2014-05-27 HR HRP20171961TT patent/HRP20171961T1/hr unknown
- 2014-05-27 MX MX2015016428A patent/MX361538B/es active IP Right Grant
- 2014-05-27 LT LTEP14727036.7T patent/LT3004090T/lt unknown
- 2014-05-27 TW TW103118498A patent/TWI653235B/zh not_active IP Right Cessation
- 2014-05-27 WO PCT/GB2014/051607 patent/WO2014191726A1/en not_active Ceased
- 2014-05-27 UY UY0001035590A patent/UY35590A/es not_active Application Discontinuation
- 2014-05-27 DK DK14727036.7T patent/DK3004090T3/en active
- 2014-05-27 PE PE2015002429A patent/PE20160874A1/es active IP Right Grant
- 2014-05-27 PL PL14727036T patent/PL3004090T3/pl unknown
- 2014-05-27 HU HUE14727036A patent/HUE035738T2/en unknown
- 2014-05-27 JP JP2016516235A patent/JP6286031B2/ja not_active Expired - Fee Related
- 2014-05-27 ES ES14727036.7T patent/ES2654161T3/es active Active
- 2014-05-27 US US14/287,332 patent/US9155727B2/en not_active Expired - Fee Related
- 2014-05-27 BR BR112015029455A patent/BR112015029455A8/pt not_active Application Discontinuation
- 2014-05-27 CA CA2911859A patent/CA2911859A1/en not_active Abandoned
- 2014-05-27 TN TN2015000516A patent/TN2015000516A1/en unknown
- 2014-05-27 ME MEP-2017-292A patent/ME02892B/me unknown
- 2014-05-27 CN CN201480028785.1A patent/CN105229004B/zh not_active Expired - Fee Related
- 2014-05-27 SG SG11201509393VA patent/SG11201509393VA/en unknown
- 2014-05-27 AU AU2014272856A patent/AU2014272856B2/en not_active Ceased
-
2015
- 2015-08-31 US US14/840,342 patent/US9616050B2/en not_active Expired - Fee Related
- 2015-11-11 DO DO2015000274A patent/DOP2015000274A/es unknown
- 2015-11-12 IL IL242559A patent/IL242559B/en not_active IP Right Cessation
- 2015-11-24 PH PH12015502615A patent/PH12015502615A1/en unknown
- 2015-11-27 CL CL2015003491A patent/CL2015003491A1/es unknown
- 2015-11-27 NI NI201500167A patent/NI201500167A/es unknown
- 2015-11-30 CR CR20150629A patent/CR20150629A/es unknown
-
2017
- 2017-02-28 US US15/445,000 patent/US10130617B2/en not_active Expired - Fee Related
-
2018
- 2018-01-03 CY CY20181100009T patent/CY1120474T1/el unknown
- 2018-10-12 US US16/158,527 patent/US20190038607A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120474T1 (el) | Χημικες ενωσεις | |
| CY1124726T1 (el) | Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv | |
| CY1121706T1 (el) | Ενωσεις υποκατασταθεισες διυδροϊσοκινολινονης | |
| CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
| CY1120031T1 (el) | Αποπτωτικοι υποκινητες ν-ακυλοσουλφοναμιδης | |
| CY1120734T1 (el) | Στερεες μορφες ενος εκλεκτικου αναστολεα cdk4/6 | |
| BR112017013491A2 (pt) | compostos de pirimidina fundida para o tratamento de hiv | |
| TN2015000313A1 (en) | Chemical compounds | |
| EA201690316A1 (ru) | Соединения для применения в качестве иммуномодуляторов | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| CY1121804T1 (el) | Καινοτομες ενωσεις πυριμιδινης και πυριδινης και η χρηση τους | |
| EA201790024A1 (ru) | Модуляторы toll-подобных рецепторов для лечения вич | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| MX377916B (es) | Compuestos 4-amino-imidazoquinolina. | |
| EA201591728A1 (ru) | Гетероциклические соединения и способы их применения | |
| CY1117105T1 (el) | Ενωσεις πυριδαζινονης και χρηση τους ως αναστολεις του daao | |
| EA201600124A1 (ru) | Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
| CY1122313T1 (el) | Ορβεπιταντη για την αγωγη του χρονιου κνησμου | |
| EA201692358A1 (ru) | Производные изоиндолина для применения в лечении вирусной инфекции | |
| EA201890331A1 (ru) | Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена | |
| CY1122077T1 (el) | Νεα δακτυλιωμενα φαινοξυακεταμιδια | |
| EA201600434A1 (ru) | Применение производных бензимидазолпролина | |
| EA201650003A1 (ru) | Соединённые циклоалкилом дигетероциклические производные | |
| EA201690294A1 (ru) | Новые соединения и их применение для получения tau-визуализирующих агентов и tau-визуализирующих составов |